Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given an average rating of “Moderate Buy” by the ten ...
The Pharma Letter23h
The week in pharma: action, reaction and insight – week to January 10
Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...